Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × X-Rays × Thoracic × Clear all

Phase

Phase NA 17 Phase 1 5 Phase 2 4 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Sarcoma 4 Genitourinary 3 Gynecologic 2 CNS 2 Thoracic 1 Other hematologic neoplasm 1 NET 1 Lymphoid 1 Endocrine 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 282 Cisplatin 225 Pemetrexed 196 Paclitaxel 151 Docetaxel 130 pembrolizumab 108 Gemcitabine 94 Etoposide 63 Erlotinib Hydrochloride 59 Radiotherapy 54 Vinorelbine 47 Gefitinib 46 Bevacizumab 46 durvalumab 45 atezolizumab 41 Nivolumab 39 Drug Therapy 34 osimertinib 30 Topotecan 29 tislelizumab 23 130-nm albumin-bound paclitaxel 23 Radiosurgery 20 Ipilimumab 18 Crizotinib 18 Magnetic Resonance Spectroscopy 15 Albumin-Bound Paclitaxel 15 Surgical Procedures, Operative 14 aumolertinib 13 Platinum 13 Injections 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499674 2026-03-30

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡